We are live on ! Find out more
BI

BVF Inc Portfolio holdings

AUM $3.14B
1-Year Est. Return 249.53%
This Fund
S&P 500
This Quarter Est. Return
+7.57%
1 Year Est. Return
+249.53%
3 Year Est. Return
+690.11%
5 Year Est. Return
+1,011.36%
10 Year Est. Return
+22,702.25%
AUM
$1.84B
AUM Growth
+$214M
Cap. Flow
+$218M
Cap. Flow %
11.89%
Top 10 Hldgs %
45.79%
Holding
65
New
8
Increased
23
Reduced
12
Closed
3

Top Buys

Rank Stock Value
1
RLAY icon
Relay Therapeutics
RLAY
+$129M
2
KYMR icon
Kymera Therapeutics
KYMR
+$80.3M
3
CYTK icon
Cytokinetics
CYTK
+$77.7M
4
RVMD icon
Revolution Medicines
RVMD
+$36.1M
5
RPTX
Repare Therapeutics
RPTX
+$29.7M

Top Sells

Rank Stock Value
1
PRNB
Principia Biopharma Inc. Common Stock
PRNB
+$88.8M
2
ARGX icon
argenx
ARGX
+$53M
3
IONS icon
Ionis Pharmaceuticals
IONS
+$38.2M
4
KURA icon
Kura Oncology
KURA
+$28.4M
5
BDTX icon
Black Diamond Therapeutics
BDTX
+$16M

Sector Composition

Rank Sector Weight
1 Healthcare 98.4%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CTMX icon
26
CytomX Therapeutics
CTMX
$681M
$23.7M 1.29%
3,559,722
+444,185
+14% +$3.29M
MTEM
27
DELISTED
Molecular Templates, Inc.
MTEM
$23.5M 1.28%
143,270
– –
CBIO
28
Crescent Biopharma
CBIO
$527M
$22.2M 1.21%
72,443
– –
RNAC icon
29
Cartesian Therapeutics
RNAC
$224M
$21M 1.14%
281,985
+5,500
+2% +$421K
OVID icon
30
Ovid Therapeutics
OVID
$420M
$20.8M 1.13%
3,622,051
+1,229,900
+51% +$8.23M
EPIX
31
DELISTED
ESSA Pharma
EPIX
$20.7M 1.13%
3,005,589
+1,020,700
+51% +$6.93M
INFI
32
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$20.4M 1.11%
17,426,968
– –
ANAB icon
33
AnaptysBio
ANAB
$1.57B
$18.1M 0.99%
1,227,405
-66,996
-5% -$1.21M
CALT
34
DELISTED
Calliditas Therapeutics AB American Depositary Shares
CALT
$18M 0.98%
750,000
– –
CALA
35
DELISTED
Calithera Biosciences, Inc
CALA
$15.8M 0.86%
229,282
-125,250
-35% -$10.9M
SPRO icon
36
Spero Therapeutics
SPRO
$68.9M
$15M 0.82%
1,344,334
+857,794
+176% +$10.1M
CTIC
37
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$14.9M 0.81%
6,929,690
– –
PNT
38
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
$14.4M 0.78%
+1,000,000
New +$13.6M
VSTM icon
39
Verastem
VSTM
$489M
$13M 0.71%
895,666
+476,583
+114% +$7.89M
LITS
40
Lite Strategy Inc
LITS
$33.3M
$12.7M 0.69%
204,008
-2,500
-1% -$151K
PHAT icon
41
Phathom Pharmaceuticals
PHAT
$717M
$11.8M 0.64%
322,098
– –
PVLA
42
Palvella Therapeutics
PVLA
$2.04B
$11.4M 0.62%
68,682
+29,740
+76% +$6.77M
CDTX
43
DELISTED
Cidara Therapeutics
CDTX
$10.7M 0.58%
188,335
+3,875
+2% +$274K
PANA.U
44
DELISTED
Panacea Acquisition Corp. Units, each consisting of one share of Class A common stock and one-third
PANA.U
$9.6M 0.52%
+800,000
New +$9.21M
GNCA
45
DELISTED
Genocea Biosciences, Inc.
GNCA
$9.19M 0.5%
4,012,404
+1,994,006
+99% +$5.23M
GMDA
46
DELISTED
Gamida Cell Ltd. Ordinary Shares
GMDA
$8.9M 0.48%
2,143,667
– –
CFRX
47
DELISTED
ContraFect Corporation
CFRX
$8.45M 0.46%
20,000
– –
TNGX icon
48
Tango Therapeutics
TNGX
$4.43B
$8.29M 0.45%
+800,000
New +$8.17M
CRVS icon
49
Corvus Pharmaceuticals
CRVS
$1.12B
$6.99M 0.38%
1,743,712
+1,600
+0.1% +$6.39K
EVLO
50
DELISTED
Evelo Biosciences, Inc. Common Stock
EVLO
$6.85M 0.37%
65,000
– –
1
2
3

Similar funds

GKWIM
Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return
BP
BNP Paribas Paris, France $3.15B AUM 22.54% 1-Year Est. Return
LFG
Larson Financial Group St Louis, Missouri $3.13B AUM 22.88% 1-Year Est. Return
DIG
DeepCurrents Investment Group New York $3.12B AUM 12.93% 1-Year Est. Return
CCI
Cevian Capital II St. Helier, Jersey $3.12B AUM 25.62% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return
BFA
Bragg Financial Advisors Charlotte, North Carolina $3.16B AUM 26% 1-Year Est. Return

BVF Inc's Q3 2020 Portfolio in Review

As of Q3 2020, BVF Inc held 65 positions worth $1.84B, up 13% from $1.62B the previous quarter. Its ten largest holdings account for 46% of the portfolio.

BVF Inc deployed $218M of net new capital in Q3 2020, opening 8 new positions and adding to 23 existing holdings. Its largest new stake was Relay Therapeutics: 3,378,380 shares worth $144M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 97% a quarter earlier.

On the sell side, the largest reduction was argenx, an estimated $53M trimmed.

  • BVF Inc's largest Q3 2020 buy was Relay Therapeutics: 3,378,380 shares worth $144M.
  • BVF Inc added most to Revolution Medicines in Q3 2020, an estimated $36.1M increase.
  • BVF Inc's biggest Q3 2020 reduction was argenx, cutting an estimated $53M.
  • BVF Inc fully exited Principia Biopharma Inc. Common Stock in Q3 2020, selling an estimated $88.8M.
  • BVF Inc's ten largest holdings make up 46% of its $1.84B portfolio in Q3 2020.
  • BVF Inc opened 8 new positions and closed 3 in Q3 2020.
  • BVF Inc's portfolio value rose 13% quarter-over-quarter to $1.84B.

Based on BVF Inc's 13F filing for Q3 2020, filed 13 Nov 2020.